Table 2.
Characteristics of People Living With Human Immunodeficiency Virus Initiating Antiretroviral Therapy of ≥45 Days’ Duration, 2007–2016, in Participating North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) Cohorts (Those With ≥50 Individuals Receiving Each Active Agent), Stratified by Active Agent of Regimen Core
| Characteristic | Total No. | NNRTI-Based (n = 9982) |
PI-Based (n = 5375) |
RAL-Based (n = 1081) |
DTG-Based (n = 1210) |
EVG-Based (n = 2315) |
Combined (N = 19 963) |
Interagent P Value |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex assigned at birth | 20 032 | <.001a | ||||||||||||
| Male | 0.91 | (9084) | 0.82 | (4410) | 0.85 | (917) | 0.86 | (1044) | 0.89 | (2058) | 0.88 | (17 513) | ||
| Female | 0.09 | (898) | 0.18 | (965) | 0.15 | (164) | 0.14 | (166) | 0.11 | (257) | 0.12 | (2450) | ||
| Race/ethnicity | 19 347 | <.001a | ||||||||||||
| White, non-Hispanic | 0.40 | (3842) | 0.38 | (1954) | 0.46 | (487) | 0.38 | (446) | 0.37 | (834) | 0.39 | (7563) | ||
| Non-white | 0.60 | (5767) | 0.62 | (3214) | 0.54 | (567) | 0.62 | (740) | 0.63 | (1427) | 0.61 | (11 715) | ||
| HIV transmission risk | 20 032 | <.001a | ||||||||||||
| MSM | 0.40 | (4007) | 0.36 | (1914) | 0.43 | (462) | 0.60 | (725) | 0.59 | (1357) | 0.42 | (8465) | ||
| IDU, including MSM/IDU | 0.12 | (1173) | 0.16 | (846) | 0.13 | (139) | 0.05 | (63) | 0.07 | (155) | 0.12 | (2376) | ||
| Heterosexual | 0.14 | (1405) | 0.21 | (1147) | 0.17 | (186) | 0.21 | (250) | 0.19 | (436) | 0.17 | (3424) | ||
| Other/unknown | 0.34 | (3397) | 0.27 | (1468) | 0.27 | (294) | 0.14 | (172) | 0.16 | (367) | 0.28 | (5698) | ||
| Ageb, y | 20 032 | 42 (32, 51) | 42 (32, 51) | 44 (33, 52) | 35 (28, 48) | 34 (27, 45) | 41 (31, 50) | <.001c | ||||||
| Baseline weightb, kg | 16 785 | 78 (69, 89) | 77 (67, 88) | 78 (68, 90) | 76 (67, 89) | 77 (67, 90) | 78 (68, 89) | <.001c | ||||||
| Weight at 1 y after ARTb, kg | 15 234 | 80 (70, 92) | 80 (70, 92) | 81 (72, 94) | 80 (71, 93) | 80 (69, 93) | 80 (70, 92) | .087c | ||||||
| Baseline BMIb, kg/m2 | 16 186 | 25 (22, 28) | 25 (22, 28) | 26 (23, 29) | 25 (22, 29) | 25 (22, 29) | 25 (22, 28) | .006c | ||||||
| Baseline CD4+ countb, cells/µL | 16 710 | 319 (184, 464) | 259 (102, 415) | 332 (158, 492) | 396 (188, 594) | 380 (214, 554) | 315 (162, 475) | <.001c | ||||||
| Baseline log10 HIV-1 RNAb | 15 711 | 4.6 (4.0, 5.0) | 4.7 (4.1, 5.2) | 4.6 (4.0, 5.1) | 4.6 (4.1, 5.1) | 4.6 (4.1, 5.2) | 4.6 (4.1, 5.1) | <.001c | ||||||
| Year of ART initiationb | 20 032 | 2010 (2008, 2012) | 2010 (2008, 2012) | 2011 (2010, 2013) | 2016 (2015, 2016) | 2014 (2014, 2015) | 2011 (2009, 2013) | <.001c | ||||||
| Incident diabetes mellitus | 20 032 | .01a | ||||||||||||
| No | 0.97 | (9634) | 0.96 | (5163) | 0.95 | (1028) | 0.98 | (1185) | 0.98 | (2267) | 0.97 | (19 277) | ||
| Yes | 0.03 | (348) | 0.04 | (212) | 0.05 | (53) | 0.02 | (25) | 0.02 | (48) | 0.03 | (686) | ||
| Follow-up timeb, y | 20 032 | 3.01 (1.19, 5.22) | 2.08 (0.86, 4.32) | 2.51 (1.10, 4.68) | 1.15 (0.62, 1.91) | 1.54 (0.79, 2.72) | 2.23 (0.94, 4.41) | <.001c |
Numbers in parentheses after proportions are frequencies. N is the number of nonmissing values.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; DTG, dolutegravir; EVG, elvitegravir; HIV, human immunodeficiency virus; HIV-1, human immunodeficiency virus type 1; IDU, injection drug use; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RAL, raltegravir.
aPearson χ 2 test.
bMedian (lower quartile, upper quartile).
cKruskal-Wallis test.